Antibody Fragments are known to have vast therapeutic applications. They are useful in medical diagnostics as well. Until now, whole or full-length antibodies have grabbed a major share in the global biopharmaceuticals market. But recently, it has been discovered that in many conditions, Antibody Fragments can be more suitable for use than whole antibodies because of their smaller size.
For instance, due to their large size, anti-tumor antibodies fail to penetrate the tumor, which in turn affects their therapeutic value in tumor suppression. As Antibody Fragments have a smaller size, they exhibit better penetration. Moreover, they offer some additional benefits such as low manufacturing cost, extended therapeutic use, and high yield in production.
Antibody Fragments are presently being used for treating central nervous system disorders, immune deficiencies, cardiovascular diseases, and cancer such as breast cancer and colorectal cancer. The global Antibody Fragments market is expected to grow at a CAGR of 8.5% during 2019 to 2026 and reach USD 29,673.3 million by the end of 2026.
At present, the Antibody Fragments market is at as a nascent stage. But increasing investment in R&D is expected to propel the growth of the market in the coming days. Presently, research on Antibody Fragments is targeted towards cancer and therefore, the growing prevalence of cancer across the globe will drive the growth of the Antibody Fragments market.
The advantages of Antibody Fragments over full length antibodies will also give a major boost to the growth of the market. Further, the increasing geriatric population, growing incidence of infectious diseases and immune deficiencies, and development of new Antibody Fragments will affect the market favourably.
The manufacturing and purification costs of Antibody Fragments are lesser than those of full-chain antibodies. Therefore, it is expected that in the coming days, Antibody Fragments will be preferred more than the full-chain antibodies. However, stringent regulatory guidelines for approving Antibody Fragments and for using some Antibody Fragments may impede the growth of the market to some extent.
Geographically, both North America and Europe will play a major role in the global Antibody Fragments market as these regions record a higher incidence of cancer and other immune deficiency disorders and consequently, higher spending on drugs and therapies related to cancer. So, naturally North America is the largest market for Antibody Fragments, followed by Europe and Asia-Pacific.
The major players that have been dominating the Antibody Fragments market include Novartis AG, Johnson & Johnson, Inc., Amgen Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Ltd., Biogen Inc., Sanofi, and Eli Lilly and Co., among others.